De-intensification of blood glucose lowering medication in people identified as being over-treated: A mixed methods study
Hart, Huberta E.; Ditzel, Kim; Rutten, Guy E.; de Groot, Esther; Seidu, Samuel; Khunti, Kamlesh; Vos, Rimke C.
(2019) Patient Preference and Adherence, volume 13, pp. 1775 - 1783
(Article)
Abstract
Aim: To evaluate if, one year after notification of possible overtreatment, diabetes care providers de-intensified glucose-lowering medications and to gain insight into the opinions and beliefs of both care providers and patients regarding de-intensification. Methods: Mixed methods using routine care data from five health-care centres in the Netherlands. Patient characteristics
... read more
and medication prescription of patients, previously identified as possibly over-treated, were extracted from patients’ medical records. Opinions of care providers were obtained through interviews. Patients received questionnaires about their diabetes treatment and were asked to participate in focus groups. Results: A total of 64 elderly patients with type 2 diabetes were previously identified as possibly over-treated and included; 57.8% male, median age 75 years (IQR=72–82), median diabetes duration 12 years (IQR=8–18). De-intensification was implemented in more than half (n=36) of them. Care providers preferred person-centred care above just setting general HbA1c target values, considering patient characteristics (such as comorbidity) and patient’s preference. Patients valued glucose levels as most important in determining their treatment. Both patients and care providers felt that de-intensification should occur gradually. Conclusion: Treatment had been de-intensified in more than half of the patients (56.3%). Insight in reasons for not de-intensifying elderly patients is important since treatment for them can be “person-centred care”. De-intensification is an iterative and time-intensive process.
show less
Download/Full Text
Keywords: Elderly, Hypoglycaemia, Insulin therapy, Overtreatment, Primary care, Type 2 diabetes, Medicine (miscellaneous), Social Sciences (miscellaneous), Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Health Policy
ISSN: 1177-889X
Publisher: Dove Medical Press Ltd.
Note: Funding Information: KK has acted as a consultant, speaker or received grants in support for research from Amgen, Novartis, Novo Nordisk, Sanofi-Aventis, Boehringer Ingelheim, Lilly, Pfizer and Merck Sharp & Dohme. SS has acted as consultant, advisory board member and speaker for Novo Nordisk, Amgen, Sanofi-Aventis, Lilly, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca and Janssen, NAPP and Novartis. He has received research grants from Jansen Pharm. SS and KK are supported by the NIHR Collaboration for Leadership in Applied Health Research and Care East Midlands (CLAHRC EM) and the NIHR Leicester, Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. GER and RCV report grants from PCDE, during the conduct of the study. RCV also reports grants from Sanofi, outside the submitted work. The authors report no other conflicts of interest in this work. Funding Information: This study was initiated and completed independently by Primary Care Diabetes Study Group of the European Association for the Study of Diabetes with full funding from Primary Care Diabetes Europe (PCDE). PCDE has received corporate gold sponsorship from Eli Lilly and Astra Zeneca and silver sponsorship from Roche. Publisher Copyright: © 2019 Hart et al.
(Peer reviewed)